At Home Group is a holding company. Through its subsidiaries, the company is a home decor superstore. The company's product mix includes home furnishings, which consists of accent furniture, furniture, mirrors, patio cushions, rugs and wall art. Accent decor consists of artificial flowers and trees, bath, bedding, candles, garden and outdoor decor, holiday accessories, home organization, pillows, pottery, vases and window treatments. The company operates its stores primarily in the South Central, Southeastern, Mid-Atlantic and Midwestern regions of the U.S. In addition, the company operates a distribution center and warehouse premises in Texas, which services its stores, and a second distribution center in Pennsylvania.

Corporate Office Properties Trust is a real estate investment trust. Corporate Office Properties, L.P. (COPLP) and subsidiaries is the entity through which the company, the sole general partner of COPLP, conducts almost all of its operations and owns almost all of its assets. The company owns, manages, leases, develops and selectively acquires office and data center properties. The majority of the company's portfolio is in locations that support the United States Government and its contractors that engaged in national security, defense and information technology related activities servicing. The company also owns office properties in select urban/urban-like submarkets in the Greater Washington, DC/Baltimore region.

Eyenovia is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing the company's patented piezo-print delivery technology, branded the Optejet?. The company's MicroStat is a fixed combination formulation of phenylephrine-tropicamide for mydriasis (pupil dilation). MicroPine is a topical therapy for the treatment of progressive myopia. MicroProst is a latanoprost formulation for lowering intraocular pressure in patients with ocular hypertension, primary open angle glaucoma, and chronic angle closure glaucoma. MicroTears is the company's over-the-counter product candidate for hyperemia (red eye), pruritis (itch) and dry eye.

Golub Capital BDC is registered as an externally managed, closed-end, non-diversified management investment company. The company makes investments primarily in one stop (a loan that combines characteristics of first lien senior secured loans and second lien or subordinated loans) and other senior secured loans of middle-market companies that are, in most cases, sponsored by private equity firms. The company's investment objective is to generate existing income and capital appreciation by investing primarily in one stop and other senior secured loans of United States middle-market companies.

Hartford Financial Services Group is a holding company. Through its subsidiaries, the company provides property and casualty insurance, group benefits insurance and services, and mutual funds and exchange-traded products. The company has five segments: Commercial Lines, which provides automobile, property, general liability, and marine coverages; Personal Lines, which provides automobile and homeowners coverages; Property and Casualty Other Operations, which provides group life, group disability, and other products; and Hartford Funds, which provides mutual fund, exchange-traded products, and Talcott Resolution life and annuity separate accounts.

Kodiak Sciences is a clinical stage biopharmaceutical company focusing on therapeutics to treat chronic, high-prevalence retinal diseases. The company's main product candidate is KSI-301, a biologic therapy built with the company's antibody biopolymer conjugate platform, which is designed to maintain drug levels in ocular tissues. KSI-301 is used to treat patients with wet age-related macular degeneration, diabetic retinopathy, including diabetic macular edema, and macular edema due to retinal vein occlusion. The company has applied its antibody biopolymer conjugate platform to develop additional product candidates beyond KSI-301, including KSI-501, its bispecific anti-IL-6/VEGF bioconjugate.

Pure Cycle is a wholesale water and wastewater company. The company provides wholesale water and wastewater services; designs, constructs, operates and maintains water and wastewater systems; supplies untreated water for hydraulic fracturing and other commercial/industrial uses; and operates a land development segment that is developing a master planned mixed-use community. The company owns or controls the infrastructure required to withdraw, treat, store and deliver water (such as wells, diversion structures, pipelines, reservoirs and treatment facilities); collect, treat, store and reuse wastewater; and treat and deliver reclaimed water for irrigation use.

Safety Insurance Group is a holding company. Through its subsidiaries, the company is a provider of private passenger, commercial automobile and homeowners insurance in Massachusetts. The company's product lines include: Private Passenger Automobile, which provides coverage for bodily injury and property damage to others, no-fault personal injury coverage for the insured/insured's car occupants, and physical damage coverage for an insured's own vehicle for collision or other perils; Commercial Automobile, which provides insurance for commercial vehicles used for business purposes; and Inland Marine, which provides inland marine coverage as an endorsement for all homeowners and business owner policies.

Tejon Ranch is a real estate development and agribusiness company. The company's segments are: Real Estate-Commercial/Industrial, which is involved in building, land lease activities, and land and building sales; Real Estate-Resort/Residential, which is involved in the land entitlement and development process internally and through a joint venture; mineral resources, which includes oil and gas royalty leases, rock and aggregate mining leases, a lease with National Cement and sales of water; Farming Operations, which is engaged in the sale of wine grapes, almonds and pistachios; and Ranch Operations, which consists of game management and ancillary land uses such as grazing leases and filming.

TRACON Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of targeted therapeutics for cancer and wet age-related macular degeneration. The company is developing its primary product candidate, TRC105 (carotuximab), an endoglin antibody, for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor pathway, or in combination with inhibitors of the programmed cell death protein 1 pathway. The company's second clinical stage product oncology candidate is TRC102, a small molecule being developed for the treatment of lung cancer and mesothelioma.